SCHEMBL16600128

SCHEMBL16600128

O=CC(O)CC(O)C(O)CCO

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.46
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17105637 1.00 AKR1B1 (0.46) AKR1B1THRB
SCHEMBL9910548 0.84 AKR1B1 (0.53) AKR1B1
SCHEMBL25916469 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL16600332 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL1747065 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL5319919 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL1658629 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL447075 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL319227 0.80 AKR1B1 (0.57) AKR1B1
SCHEMBL23839827 0.78 AKR1B1 (0.48) AKR1B1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2025-04-24 US disclosed
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo ENGENE, INC. (CA) 2024-09-03 US disclosed
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2022-05-05 US disclosed
EP-3970697-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO Engene, Inc. (CA) 2022-03-23 EP disclosed
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo HERCULES CAPITAL, INC. 2021-11-09 US disclosed
EP-3049473-B1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO ENGENE INC (CA) 2021-09-22 EP disclosed
US-20200061208-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2020-02-27 US disclosed
US-10456481-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo HERCULES CAPITAL, INC. 2019-10-29 US disclosed
US-20180344875-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2018-12-06 US disclosed
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2016-08-18 US disclosed
EP-3049473-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO Engene, Inc. (CA) 2016-08-03 EP disclosed
WO-2015042711-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO ENGENE, INC. (CA) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061208-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-20180344875-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-10456481-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP AKR1B1 3046/4885THRB 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.